DOT1L：通过 BRCA1 协调甲基化依赖性放射治疗反应。
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1.
发表日期：2024 Oct 09
作者：
Justin W Leung, Kyle M Miller
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES
摘要：
乳腺癌 1 型易感蛋白 (BRCA)-1 存在于几种功能不同的复合物中，促进 DNA 双链断裂 (DSB) 的 DNA 修复。 Tang 及其同事最近的一项研究发现，赖氨酸甲基转移酶 Disruptor of Telomeric Silencing 1-Like (DOT1L) 参与修饰受体相关蛋白 80 (RAP80)，以促进 BRCA1-A 复合物定位和 DNA 断裂时的修复功能。这项研究阐明了癌症放射治疗的潜在治疗靶点。版权所有 © 2024 Elsevier Ltd. 保留所有权利。
Breast Cancer Type 1 Susceptibility Protein (BRCA)-1 existing in several functionally distinct complexes, promotes DNA repair of DNA double-strand breaks (DSBs). A recent study by Tang and colleagues identifies the lysine methyltransferase Disruptor of Telomeric Silencing 1-Like (DOT1L) involved in modifying Receptor-Associated Protein 80 (RAP80) to promote BRCA1-A complex localization and repair functions at DNA breaks. This study illuminates a potential therapeutic target for cancer radiotherapy.Copyright © 2024 Elsevier Ltd. All rights reserved.